ArticleCancer science2009
Clinicopathological relevance of UbcH10 in breast cancer.
Article in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- The Chromosome Passenger Complex (CPC) Components and Its Associated Pathways Are Promising Candidates to Differentiate Between Normosensitive and Radiosensitive ATM-Mutated Cells.Biomarker insights · 2024Article
- UBE2C Drives Human Cervical Cancer Progression and Is Positively Modulated by mTOR.Biomolecules · 2020Article
- UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer.Frontiers in oncology · 2019Article
- The importance of regulatory ubiquitination in cancer and metastasis.Cell cycle (Georgetown, Tex.) · 2017Review
- Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types.Scientific reports · 2015Article
- Crosstalk analysis of pathways in breast cancer using a network model based on overlapping differentially expressed genes.Experimental and therapeutic medicine · 2015Article
- UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in esophageal cancer.Oncology letters · 2015Article
- Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.International journal of molecular sciences · 2015Article
- UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer.Scientific reports · 2014Article
- The master cell cycle regulator APC-Cdc20 regulates ciliary length and disassembly of the primary cilium.eLife · 2014Article
- Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.PloS one · 2014Article
- Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.PloS one · 2014Article
- Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.Cellular oncology (Dordrecht, Netherlands) · 2013Article
- Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer.Molecular biology reports · 2013Article
- UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy.International journal of clinical and experimental pathology · 2013Article
- K11-linked ubiquitin chains as novel regulators of cell division.Trends in cell biology · 2011Review
- Identification of a physiological E2 module for the human anaphase-promoting complex.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer.BMC cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abrogated mitotic progression is a common hallmark of cancer. UbcH10, one of the components of the ubiquitin/proteasome pathway, plays a pivotal role in the regulation of mitotic progression. Abnormal UbcH10 activity is reported in certain types of human cancers; its overexpression is occasionally encountered in cancerous tissue compared with adjacent normal tissue. Current studies have suggested the critical role of UbcH10 in the spindle assembly checkpoint and the subsequent accurate separation of sister chromatids, which is orchestrated by a series of molecular interactions governed by the complex and diverse cell cycle machinery. To validate the potential role of UbcH10 in cell proliferation in cancer, we have analyzed the clinicopathological relevance of UbcH10 in progression of breast cancer using a combinatorial approach of human tumor arrays and biochemical analyses. Our results show that the percentage of tested samples which stained positive for UbcH10 in breast cancer tissues is significantly higher compared to the adjacent nonmalignant tissue. Furthermore, results from the clinicopathological analysis have revealed that elevated expression of UbcH10 is associated with higher histological grade tumors. In addition, depletion of UbcH10 by RNA interference in breast cancer cells resulted in decreased cellular proliferation, while overexpression of UbcH10 significantly enhanced cellular growth in breast cancer. Our results suggest a pathological correlation between UbcH10 and cell proliferation in breast cancer. Thus, aberrant UbcH10 activity may induce the dysfunction of proper cell cycle progression and result in the aggressive behavior of tumor cells in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.